QUANTITATIVE FECAL FAT EXCRETION IN CHRONIC PANCREATITIS SUBJECTS

慢性胰腺炎受试者粪便脂肪排泄的定量

• 批准号: 7950731
• 负责人: Phillip TOSKES
• 金额: $ 1.03万
• 依托单位: UNIVERSITY OF FLORIDA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950731
• 关键词: Carotene; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Disease; Enzymes; Excretory function; Fatty acid glycerol esters; Funding; Future; Gold; Grant; Hour; Institution; Intervention; Malabsorption Syndromes; Measurement; Patients; Relative (related person); Research; Research Personnel; Resources; Screening procedure; Secretin; Serum; Source; Staining method; Stains; Steatorrhea; Symptoms; Testing; Trypsin; United States National Institutes of Health; chronic pancreatitis

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In order to answer the question: are currently available screening tests for fat malabsorption adequate to detect steatorrhea, increased fecal fat excretion, >7g of fat per day, quantitatively, in patients with chronic pancreatitis, we propose to do a study comparing the 72 hour quantitative fecal fat excretion measurement to four screening tests. The most commonly used screening tests are: serum carotene, qualitative fecal fat stain, serum trypsin and the secretin stimulation test. It was our observation, from previous studies, that the screening tests led to false positive results in approximately 50% of our subjects compared to the quantitative fecal fat excretion measurement. Patients with chronic pancreatitis may have similar symptoms whether they have mild to moderate or severe disease. The ability to adequately categorize these patients into the two groups is important in both the clinical and research setting. In our ongoing and future studies, it is mandated that we have subjects with severe chronic pancreatitis and steatorrhea therefore, it is imperative that we accurately categorize our subjects. Clinically, it is important to know because enzyme treatment and other interventions achieve different results in patients with severe disease versus mild to moderate disease. We expect this study to definitely define the relative accuracy of these screening tests compared to the quantitative fecal fat excretion measurement, which is the gold standard.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 为了回答这个问题：目前可用的脂肪吸收不良筛查试验是否足以定量检测慢性胰腺炎患者的脂肪代谢异常、粪便脂肪排泄增加、> 7 g/天的脂肪，我们建议进行一项研究，将72小时定量粪便脂肪排泄测量与四种筛查试验进行比较。 最常用的筛查试验有：血清胡萝卜素、粪脂肪染色定性、血清胰蛋白酶和胰泌素刺激试验。 我们从以前的研究中观察到，与定量粪便脂肪排泄测量相比，筛选试验导致约50%的受试者出现假阳性结果。 慢性胰腺炎患者可能有类似的症状，无论他们有轻度至中度或重度疾病。 将这些患者充分分类为两组的能力在临床和研究环境中都很重要。在我们正在进行的和未来的研究中，我们必须有患有重度慢性胰腺炎和脂肪肝的受试者，因此，我们必须准确地对受试者进行分类。 在临床上，了解这一点很重要，因为酶治疗和其他干预措施在重度疾病患者与轻度至中度疾病患者中取得了不同的结果。 我们希望这项研究能够明确定义这些筛查试验与定量粪便脂肪排泄测量（金标准）相比的相对准确性。